NCI Budget Update

Douglas R. Lowy, M.D. Principal Deputy Director National Cancer Institute Weston Ricks Director, Office of Budget and Finance National Cancer Institute

September 4, 2024 168th Regular Meeting of the National Cancer Advisory Board

Thanks to...

- Tenille McCatty, Linli Liu: NCI Office of Extramural Finance & Information Analysis
- Christine Burgess: NCI Center for Research Strategy

Making a Budget – It's Not All About Dough



What Goes Into the NCI Pie



SPORE

- Clinical Cooperative Groups
 - NCI Designated Cancer Centers
 - Career Program
 - NIH Clinical Center
 - Research Resources
- Research Project Grants
- Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs


Things That Nibble Away



 Biomedical Research and Development Price Index (BRDPI)

NCI's Research Buying Power is \$1.26B Less Than 2 Decades Ago

Even with substantial increases in recent years




Things That Nibble Away

 Biomedical Research and Development Price Index (BRDPI)



 Competing Needs Across the Federal Government

NCI Appropriations FY16 – FY24



Things That Nibble Away

- Biomedical Research and Development Price Index (BRDPI)
 - Competing Needs Across the Federal Government



Emerging Opportunities

Opportunities Over Time




- The Cancer Genome Atlas
 - TARGET Initiative
 - Center For Global Health
 - RAS Initiative
 - National Clinical Trials Network
 - NCI Community Oncology Research Program
 - Genomic Data Commons
 - Cancer Moonshot
 - Childhood Cancer Data Initiative

NCI funds many critical components of cancer research through mechanisms outside the RPGs

- A PARTIAL list:
 - SPORE grants
 - Cancer Center support grants
 - Cancer training
 - Clinical trials networks
- We need to support these mechanisms in addition to the RPGs




Increase in Unique NCI R01/R37 Applicants Data include all MPI/PIs




Sources: IMPACII analysis of PIs of R01/R37 applications (type 1, 2, 9) (12)

Percentage of modular awards has decreased progressively from 63% in 2012 to 14% (~1 in every 7 awards) in FY 2023



R01 award trends 2016-2023: Blue: Payline for experienced investigators; Green: total number of awards from unsolicited applications



Fiscal Year

2016-2023 from https://gsspubssl.nci.nih.gov/blog/articles

Early-Stage Investigators (ESI): R01/R37 payline, awards* 2016 – 2023



Fiscal Year

*Unsolicited Applications

2016-2023 from https://gsspubssl.nci.nih.gov/blog/articles

Prioritization is even more important when the budget is constrained: some examples

- Developing new standards of care vs. research to increase uptake of current standards of care
- RPG pool: Investigator-initiated awards, early stage investigators, RFA's
- Cancer training
- Cancer Center support grants: Continue with Phase III? Continue to increase the number of designated centers?
- SPORE grants
- Clinical trials networks
- Cancer disparities: in under-represented groups, rural populations, and others
- Community engagement

Prioritization: Some examples of hard choices made

- Prioritize development of new standards of care
- RPG pool: Protect new investigator-initiated awards, especially early stage investigators, reduce investment in RFAs; support noncompeting awards at <100%
- Cancer training: Maintain the number of extramural trainees through specific trainee award mechanisms

Thank you!

www.cancer.gov www.cancer.gov/espanol 1-800-4-CANCER NClinfo@nih.gov @NCIDirector @TheNCI

